Business · 02/02/2000Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for Bapten Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for Bapten, a patented animal drug product, as required by law following a submission to the Commissioner of Patents and Trademarks, Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →